• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » UPDATE: Advanced BioHealing launches Dermagraft trial

UPDATE: Advanced BioHealing launches Dermagraft trial

November 18, 2009 By MassDevice staff

From snip, snip to step, step in only a few months.

Advanced BioHealing Inc. launched a Phase III clinical trial of its Dermagraft bio-engineered skin substitute in patients with venous leg ulcers.

The Westport, Conn.-based tissue regeneration company said the Dermagraft is designed to help restore damaged tissue and support the body’s natural healing process. The Food & Drug Administration already cleared the product to treat diabetic foot ulcers; ABH said more than 1,000 wound care and outpatient clinics in the U.S. use it.

U.S. regulators earlier this week gave their go-ahead to the 16-week study, expected to be the largest randomized, controlled clinical study of bioengineered skin replacement yet. The trial aims to enroll more than 400 patients in eight countries. One group of patients will receive weekly Dermagraft applications and four-layer compression dressings, while a control group receives weekly applications of four-layer compression dressings only.

Ulcers are a frequent symptom of diabetes. Poor circulation causes blood to pool in the veins of the legs and feet where it eventually seeps out to damage surrounding tissue. Dermagraft is made with specialty cells harvested from infant foreskins removed during circumcisions. The fibroblast cells, which bind proteins between muscles and connective tissue, are seeded onto bioabsorbable mesh, where they grow to fill in the gaps of the mesh, speeding up the body’s normal healing process.

Participating facilities include Boston Medical Center and Beth Isreael Deaconesss medical center in Massachusetts, as well as five sites in Florida and three each in California and Arizona. Trials also will be conducted in seven other states. The study is scheduled to conclude by May 2010. Funding likely is coming from a $23 million private placement of debt by ABH ealier this year. Overall, the company has raised more than $36 million in equity from investors, including $25.5-million, Series C round nearly three years ago led by Safeguard Scientific Inc., a publicly traded holding company that invests in emerging technology and life-science companies.

Canaan Partners, also of Westport, and Long Island, N.Y.-based Wheatley Partners also hold significant stakes in ABH.

Filed Under: Biotech, Business/Financial News, Contract Manufacturing Tagged With: Tissue Regeneration

More recent news

  • Johnson & Johnson MedTech launches new Volt plating systems for radius, humerus
  • PharmaSens, SiBionics collab on all-in-one insulin patch pump
  • Beta Bionics to pair iLet automated insulin delivery system with Abbott’s dual glucose-ketone sensor
  • Anaconda Biomed wins CE mark for funnel catheter
  • FDA approves Neuspera neuromod for urinary incontinence

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy